FTHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Faeth Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$19.44+0.64 (+3.40%)
Close on Oct 19, 2026
- Market cap
- $109.70M
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 32.1% | -74.0% | |
| Return on assets | – | – | -61.8% | |
| Current ratio | – | 4.16 | 5.06 | |
| Interest coverage | – | -11.5× | -696.5× | |
| Diluted shares | – | 0M | 1M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Faeth Therapeutics generated $146.43M from operations and spent $13.07M on capital expenditure, dividends and share buybacks. 21% of that went back into the business.
Generated
$146.43M
Used
$13.07M
Capital expenditure$2.69M21%Dividends$00%Share buybacks$10.38M79%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$21.09M
- Cash generatingOperating cash flow above zero-$20.45M
- Return on assets improvedROA up on the prior year-40.5% → -46.5%
- Earnings backed by cashOperating cash flow above net income-$20.45M vs -$21.09M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose7.70 → 5.06
- No dilutionShare count did not rise1M → 1M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –